US · Healthcare · Biotechnology
EPS came in at -1.04 against a street estimate of -1.04 — a beat of 0.0%.
Analysts rate 4D Molecular Therapeutics Inc a strong buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $28.09.
| Fund | Stake |
|---|---|
| Jupiter Topco LLC | 10.40% |
| HHG PLC | 9.50% |
| RA Capital Management, LLC | 9.14% |
| BlackRock Inc | 8.23% |
| The Goldman Sachs Group Inc | 7.61% |
| Novo A/S | 5.88% |
| State Street Corp | 5.27% |
| Bvf Inc | 5.21% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 HEADLINE NUMBERS • 4D Molecular Therapeutics reported first-patient enrollment across multiple sites in the 4SIGHT Phase 3 trial evaluating 4D-150 fo | 2026-09-28 |
| Quarterly report · Q2 2026 4D MOLECULAR THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $70.4 million in cash; $290.9 million in short-term marke | 2026-08-13 |
| Results announced · Q3 2026 4D MOLECULAR THERAPEUTICS (FDMT) - Q2 2026 SUMMARY HEADLINE NUMBERS • Cash position: $430.6 million as of June 30, 2026 (down from $514.0 million at | 2026-08-13 |
| Company announcement · Q3 2026 4D MOLECULAR THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), Delaware incorporated, bas | 2026-07-20 |
| Material agreement · Q2 2026 4D MOLECULAR THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company secured a Loan and Security Agreement with Hercules Capital on June 24, 202 | 2026-06-29 |
| Shareholder vote results · Q2 2026 4D MOLECULAR THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Total shares outstanding (as of record date April 20, 2026): 52,274,735 common | 2026-06-22 |
| Quarterly report · Q1 2026 4D MOLECULAR THERAPEUTICS, INC. – FORM 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash & Marketable Securities: $457.6 millio | 2026-05-07 |
| Proxy statement · Q2 2026 4D MOLECULAR THERAPEUTICS, INC. – 2026 PROXY STATEMENT SUMMARY EXECUTIVE PAY • CEO David Kirn's total compensation: Document provides notice of annu | 2026-04-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for 4D Molecular Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.